Equities research analysts expect Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) to announce ($1.09) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Trillium Therapeutics’ earnings. Trillium Therapeutics reported earnings of ($0.75) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 45.3%. The firm is scheduled to issue its next quarterly earnings report on Friday, August 11th.

According to Zacks, analysts expect that Trillium Therapeutics will report full-year earnings of ($3.83) per share for the current fiscal year, with EPS estimates ranging from ($4.47) to ($2.89). For the next financial year, analysts anticipate that the business will report earnings of ($2.91) per share, with EPS estimates ranging from ($3.65) to ($2.21). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Trillium Therapeutics.

Several equities research analysts have weighed in on the company. Zacks Investment Research upgraded Trillium Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, April 6th. Ladenburg Thalmann Financial Services restated a “buy” rating and set a $18.00 price target on shares of Trillium Therapeutics in a report on Friday, June 9th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Trillium Therapeutics has an average rating of “Buy” and a consensus price target of $16.94.

A number of large investors have recently modified their holdings of TRIL. Janus Capital Management LLC increased its stake in shares of Trillium Therapeutics by 0.3% in the fourth quarter. Janus Capital Management LLC now owns 571,203 shares of the biotechnology company’s stock valued at $3,227,000 after buying an additional 1,619 shares during the period. Wells Fargo & Company MN increased its stake in shares of Trillium Therapeutics by 34.1% in the first quarter. Wells Fargo & Company MN now owns 17,700 shares of the biotechnology company’s stock valued at $109,000 after buying an additional 4,500 shares during the period. Oxford Asset Management increased its stake in shares of Trillium Therapeutics by 47.7% in the fourth quarter. Oxford Asset Management now owns 24,660 shares of the biotechnology company’s stock valued at $139,000 after buying an additional 7,967 shares during the period. Victory Capital Management Inc. increased its stake in shares of Trillium Therapeutics by 40.0% in the first quarter. Victory Capital Management Inc. now owns 77,601 shares of the biotechnology company’s stock valued at $479,000 after buying an additional 22,171 shares during the period. Finally, New Leaf Venture Partners L.L.C. bought a new stake in shares of Trillium Therapeutics during the fourth quarter valued at $547,000. Institutional investors own 31.67% of the company’s stock.

Shares of Trillium Therapeutics (NASDAQ:TRIL) opened at 4.65 on Friday. Trillium Therapeutics has a one year low of $4.45 and a one year high of $17.70. The firm’s 50-day moving average price is $5.50 and its 200-day moving average price is $5.91. The firm’s market cap is $36.48 million.

TRADEMARK VIOLATION WARNING: “Trillium Therapeutics Inc. (TRIL) Expected to Announce Earnings of -$1.09 Per Share” was published by American Banking News and is the sole property of of American Banking News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://www.americanbankingnews.com/2017/06/16/trillium-therapeutics-inc-tril-expected-to-announce-earnings-of-1-09-per-share.html.

Get a free copy of the Zacks research report on Trillium Therapeutics (TRIL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.